Chemistry:AVN-211

From HandWiki
Short description: Chemical compound
AVN-211
AVN-211 Structure.svg
Clinical data
Other namesCD-008-0173
Identifiers
CAS Number
ChemSpider
ChEMBL
Chemical and physical data
FormulaC15H15N3O2S2
Molar mass333.42 g·mol−1
3D model (JSmol)

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.[1][2][3] In early 2011, it successfully completed phase IIa clinical trials,[1][4] with benefits on positive symptoms and some procognitive effects observed,[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.[6][7][needs update]

See also

References

  1. ↑ 1.0 1.1 "Antipsychotics and the Dopamine-Serotonin Connection". Small Molecule Therapeutics for Schizophrenia. Springer. 13 October 2014. pp. 31, 37. ISBN 978-3-319-11502-3. https://books.google.com/books?id=HEzPBAAAQBAJ&pg=PA37. 
  2. ↑ Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–. ISBN 978-0-12-384977-9. https://books.google.com/books?id=1Vn2Qt6dtegC&pg=PA164. 
  3. ↑ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. 
  4. ↑ "Avineuro Pharmaceuticals, Inc. Reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia.". Avineuro Pharmaceuticals, Inc. http://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of-concept-trial-results-on-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/. 
  5. ↑ "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study". CNS Spectrums 19 (4): 316–323. August 2014. doi:10.1017/S1092852913000394. PMID 23768250. 
  6. ↑ 6.0 6.1 "Avineuro Pharmaceuticals, Inc. Announces beginning of Phase 2b clinical studies of AVN-211, potent small molecule for treatment of schizophrenia.". Avineuro Pharmaceuticals, Inc. http://www.avineuro.com/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-2b-clinical-studies-of-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/. 
  7. ↑ "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease". Molecular Pharmaceutics 13 (3): 945–963. March 2016. doi:10.1021/acs.molpharmaceut.5b00830. PMID 26886442. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:AVN-211&oldid=3338004"